Phase 2 Bladder Urothelial Carcinoma Clinical Trials
12 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–12 of 12 trials
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting
Phase 2Phase 3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled499 locationsNCT05987241
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled133 locationsNCT06770582
Recruiting
Phase 2
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Metastatic Malignant Solid NeoplasmMetastatic Bladder Urothelial CarcinomaMTAP Deletion+1 more
Northwestern University64 enrolled2 locationsNCT06630416
Recruiting
Phase 2
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled143 locationsNCT07061964
Recruiting
Phase 2
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Stage IV Bladder Cancer AJCC v7Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial Carcinoma+3 more
Mayo Clinic70 enrolled1 locationNCT07087860
Recruiting
Phase 2
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Non Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
John Sfakianos60 enrolled4 locationsNCT06503614
Recruiting
Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
Infiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial CarcinomaStage III Bladder Urothelial Carcinoma
Alliance for Clinical Trials in Oncology271 enrolled424 locationsNCT03609216
Recruiting
Phase 2
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Muscle Invasive Bladder Urothelial Carcinoma
Matthew Galsky47 enrolled5 locationsNCT06809140
Recruiting
Phase 2
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Muscle-Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8+1 more
Yuanquan Yang24 enrolled3 locationsNCT06263153
Recruiting
Phase 1Phase 2
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Triple-Negative Breast CancerNon-small Cell Lung CancerMetastatic Cancer+6 more
Hadassah Medical Organization3 enrolled1 locationNCT05296564
Recruiting
Phase 2
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
Muscle-Invasive Bladder CarcinomaMuscle Invasive Bladder Urothelial Carcinoma
Yung NA20 enrolled1 locationNCT06257017